Changes in Hong Kong stocks | Yingpai Pharmaceutical-B (07630) rose more than 3% and is expected to reduce losses by about 22% to 37% year-on-year in the medium term, and has nominated IMP2794 as PPC

The Zhitong Finance App learned that Yingpai Pharmaceutical-B (07630) rose more than 3%. As of press release, it had risen 2.64% to HK$12.43, with a turnover of HK$3.06 million.

According to the news, recently, Yingpai Pharmaceutical-B issued an announcement. According to the board's preliminary assessment of the Group's unaudited comprehensive management accounts for the six months ended June 30, 2026 (relevant period) and the information currently available to the board of directors, the Group expects to obtain revenue of about RMB 94.7 million to RMB 116 million during the relevant period, an increase of about 276% to 359% over the six months ended June 30, 2025 (same period); loss for the period was approximately RMB 81.7 million to RMB 99.9 million, compared with the same period The 129 million yuan decreased by about 37% to 22%.

Additionally, Yingpai Pharmaceutical-B announced that the company has nominated IMP2794 as a pre-clinical candidate compound (PCC) as a KAT6A-specific degradable PROTAC. IMP2794 is the first PCC discovered by Yingpai Pharmaceuticals using its own targeted protein degradation platform. IMP2794 is an efficient and selective degrading agent for KAT6A, and is more than 1000 times more selective for KAT6B. Notably, IMP2794 showed extremely high oral bioavailability in a variety of rodents and non-rodents, which indicates that it may achieve ideal drug exposure in humans.